INOVIO PHARMACEUTICALS, INC. Investing Cash Flow
INOVIO PHARMACEUTICALS, INC. (INO) reported Investing Cash Flow of $8.78 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-08-12
- INOVIO PHARMACEUTICALS, INC. net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was $6.15M, a 16.37% increase year-over-year.
- INOVIO PHARMACEUTICALS, INC. net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was $2.64M.
- INOVIO PHARMACEUTICALS, INC. net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was -$58.19K, a 100.17% decline year-over-year.
- INOVIO PHARMACEUTICALS, INC. net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was $8.87M, a 37.01% decline year-over-year.
- INOVIO PHARMACEUTICALS, INC. net cash provided by (used in) investing activities for fiscal 2025 was $14.04M, a 86.51% decline from fiscal 2024.
- INOVIO PHARMACEUTICALS, INC. net cash provided by (used in) investing activities for fiscal 2024 was $104.07M, a 19.13% increase from fiscal 2023.
- INOVIO PHARMACEUTICALS, INC. net cash provided by (used in) investing activities for fiscal 2023 was $87.36M, a 20.29% decline from fiscal 2022.
- INOVIO PHARMACEUTICALS, INC. net cash provided by (used in) investing activities for fiscal 2022 was $109.59M.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $6.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $8.78M 10-Q · filed 2026-08-12 | $8.72M derived: sum of 3 quarters · filed 2026-08-12 | $17.59M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $2.64M 10-Q · filed 2026-05-13 | $2.58M derived: sum of 2 quarters · filed 2026-05-13 | $11.44M derived: sum of 3 quarters · filed 2026-05-13 | $16.73M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | -$58.19K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $8.81M derived: sum of 2 quarters · filed 2026-03-12 | $14.09M derived: sum of 3 quarters · filed 2026-08-12 | $14.04M 10-K · filed 2026-03-12 |
| 2025-09-30 | $8.87M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $14.15M derived: sum of 2 quarters · filed 2026-08-12 | $14.10M 10-Q · filed 2025-11-10 | $48.74M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $5.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $5.23M 10-Q · filed 2026-08-12 | $39.87M derived: sum of 3 quarters · filed 2026-08-12 | $53.95M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | -$51.75K 10-Q · filed 2026-05-13 | $34.59M derived: sum of 2 quarters · filed 2026-05-13 | $48.67M derived: sum of 3 quarters · filed 2026-05-13 | $58.64M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $34.64M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $48.72M derived: sum of 2 quarters · filed 2026-03-12 | $58.69M derived: sum of 3 quarters · filed 2026-03-12 | $104.07M 10-K · filed 2026-03-12 |
| 2024-09-30 | $14.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $24.04M derived: sum of 2 quarters · filed 2025-11-10 | $69.43M 10-Q · filed 2025-11-10 | $89.37M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $9.97M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $55.35M 10-Q · filed 2025-08-12 | $75.29M derived: sum of 3 quarters · filed 2025-08-12 | $69.80M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $45.38M 10-Q · filed 2025-05-13 | $65.33M derived: sum of 2 quarters · filed 2025-05-13 | $59.83M derived: sum of 3 quarters · filed 2025-05-13 | $113.74M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $19.94M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $14.45M derived: sum of 2 quarters · filed 2025-03-18 | $68.36M derived: sum of 3 quarters · filed 2025-03-18 | $87.36M 10-K · filed 2025-03-18 |
| 2023-09-30 | -$5.49M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $48.41M derived: sum of 2 quarters · filed 2024-11-14 | $67.41M 10-Q · filed 2024-11-14 | $121.41M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $53.91M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $72.91M 10-Q · filed 2024-08-08 | $126.91M derived: sum of 3 quarters · filed 2024-08-08 | $171.46M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $19.00M 10-Q · filed 2024-05-13 | $73.00M derived: sum of 2 quarters · filed 2024-05-13 | $117.56M derived: sum of 3 quarters · filed 2024-05-13 | $107.25M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $54.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-06 | $98.56M derived: sum of 2 quarters · filed 2024-03-06 | $88.25M derived: sum of 3 quarters · filed 2024-03-06 | $109.59M 10-K · filed 2024-03-06 |
| 2022-09-30 | $44.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $34.25M derived: sum of 2 quarters · filed 2023-11-09 | $55.59M 10-Q · filed 2023-11-09 | $49.09M derived: sum of 4 quarters · filed 2024-03-06 |
| 2022-06-30 | -$10.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $11.03M 10-Q · filed 2023-08-09 | $4.53M derived: sum of 3 quarters · filed 2024-03-06 | $60.49M derived: sum of 4 quarters · filed 2024-03-06 |
| 2022-03-31 | $21.33M 10-Q · filed 2023-05-10 | $14.84M derived: sum of 2 quarters · filed 2024-03-06 | $70.80M derived: sum of 3 quarters · filed 2024-03-06 | $121.10M derived: sum of 4 quarters · filed 2024-03-06 |
| 2021-12-31 | -$6.49M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-06 | $49.46M derived: sum of 2 quarters · filed 2024-03-06 | $99.77M derived: sum of 3 quarters · filed 2024-03-06 | -$175.34M 10-K · filed 2024-03-06 |
| 2021-09-30 | $55.96M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $106.26M derived: sum of 2 quarters · filed 2022-11-08 | -$168.85M 10-Q · filed 2022-11-08 | -$172.57M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-06-30 | $50.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | -$224.81M 10-Q · filed 2022-08-09 | -$228.53M derived: sum of 3 quarters · filed 2023-03-01 | -$189.41M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-03-31 | -$275.12M 10-Q · filed 2022-05-10 | -$278.83M derived: sum of 2 quarters · filed 2023-03-01 | -$239.72M derived: sum of 3 quarters · filed 2023-03-01 | -$282.10M derived: sum of 4 quarters · filed 2023-03-01 |
| 2020-12-31 | -$3.72M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $35.40M derived: sum of 2 quarters · filed 2023-03-01 | -$6.99M derived: sum of 3 quarters · filed 2023-03-01 | -$58.80M 10-K · filed 2023-03-01 |
| 2020-09-30 | $39.11M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | -$3.27M derived: sum of 2 quarters · filed 2021-11-09 | -$55.08M 10-Q · filed 2021-11-09 | -$44.64M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | -$42.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | -$94.19M 10-Q · filed 2021-08-09 | -$83.76M derived: sum of 3 quarters · filed 2022-03-01 | -$75.49M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | -$51.81M 10-Q · filed 2021-05-10 | -$41.37M derived: sum of 2 quarters · filed 2022-03-01 | -$33.10M derived: sum of 3 quarters · filed 2022-03-01 | -$11.52M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $10.43M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $18.70M derived: sum of 2 quarters · filed 2022-03-01 | $40.29M derived: sum of 3 quarters · filed 2022-03-01 | -$9.04M 10-K · filed 2022-03-01 |
| 2019-09-30 | $8.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $29.86M derived: sum of 2 quarters · filed 2020-11-09 | -$19.48M 10-Q · filed 2020-11-09 | -$12.30M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | $21.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | -$27.75M 10-Q · filed 2020-08-10 | -$20.57M derived: sum of 3 quarters · filed 2021-03-01 | -$6.15M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | -$49.34M 10-Q · filed 2020-05-11 | -$42.15M derived: sum of 2 quarters · filed 2021-03-01 | -$27.74M derived: sum of 3 quarters · filed 2021-03-01 | -$33.72M derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-12-31 | $7.18M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $21.60M derived: sum of 2 quarters · filed 2021-03-01 | $15.62M derived: sum of 3 quarters · filed 2021-03-01 | $42.42M 10-K · filed 2021-03-01 |
| 2018-09-30 | $14.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $8.43M derived: sum of 2 quarters · filed 2019-11-12 | $35.24M 10-Q · filed 2019-11-12 | $49.82M derived: sum of 4 quarters · filed 2020-03-12 |
| 2018-06-30 | -$5.98M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $20.82M 10-Q · filed 2019-08-08 | $35.40M derived: sum of 3 quarters · filed 2020-03-12 | -$18.76M derived: sum of 4 quarters · filed 2020-03-12 |
| 2018-03-31 | $26.80M 10-Q · filed 2019-05-09 | $41.39M derived: sum of 2 quarters · filed 2020-03-12 | -$12.77M derived: sum of 3 quarters · filed 2020-03-12 | -$19.20M derived: sum of 4 quarters · filed 2020-03-12 |
| 2017-12-31 | $14.58M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | -$39.58M derived: sum of 2 quarters · filed 2020-03-12 | -$46.00M derived: sum of 3 quarters · filed 2020-03-12 | -$27.83M 10-K · filed 2020-03-12 |
| 2017-09-30 | -$54.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | -$60.58M derived: sum of 2 quarters · filed 2018-11-08 | -$42.41M 10-Q · filed 2018-11-08 | -$32.49M derived: sum of 4 quarters · filed 2019-03-12 |
| 2017-06-30 | -$6.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | $11.75M 10-Q · filed 2018-08-07 | $21.66M derived: sum of 3 quarters · filed 2019-03-12 | $30.74M derived: sum of 4 quarters · filed 2019-03-12 |
| 2017-03-31 | $18.17M 10-Q · filed 2018-05-09 | $28.09M derived: sum of 2 quarters · filed 2019-03-12 | $37.16M derived: sum of 3 quarters · filed 2019-03-12 | $34.78M derived: sum of 4 quarters · filed 2019-03-12 |
| 2016-12-31 | $9.92M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-12 | $18.99M derived: sum of 2 quarters · filed 2019-03-12 | $16.61M derived: sum of 3 quarters · filed 2019-03-12 | $16.27M 10-K · filed 2019-03-12 |
| 2016-09-30 | $9.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $6.69M derived: sum of 2 quarters · filed 2017-11-08 | $6.35M 10-Q · filed 2017-11-08 | -$14.87M derived: sum of 4 quarters · filed 2018-03-14 |
| 2016-06-30 | -$2.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | -$2.72M 10-Q · filed 2017-08-08 | -$23.94M derived: sum of 3 quarters · filed 2018-03-14 | -$25.92M derived: sum of 4 quarters · filed 2018-03-14 |
| 2016-03-31 | -$338.15K 10-Q · filed 2017-05-10 | -$21.56M derived: sum of 2 quarters · filed 2018-03-14 | -$23.54M derived: sum of 3 quarters · filed 2018-03-14 | -$52.83M derived: sum of 4 quarters · filed 2018-03-14 |
| 2015-12-31 | -$21.22M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-14 | -$23.20M derived: sum of 2 quarters · filed 2018-03-14 | -$52.49M derived: sum of 3 quarters · filed 2018-03-14 | -$54.82M 10-K · filed 2018-03-14 |
| 2015-09-30 | -$1.98M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | -$31.27M derived: sum of 2 quarters · filed 2016-11-09 | -$33.60M 10-Q · filed 2016-11-09 | -$56.82M derived: sum of 4 quarters · filed 2017-03-15 |
| 2015-06-30 | -$29.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-08 | -$31.62M 10-Q · filed 2016-08-08 | -$54.84M derived: sum of 3 quarters · filed 2017-03-15 | -$65.16M derived: sum of 4 quarters · filed 2017-03-15 |
| 2015-03-31 | -$2.33M 10-Q · filed 2016-05-09 | -$25.55M derived: sum of 2 quarters · filed 2017-03-15 | -$35.87M derived: sum of 3 quarters · filed 2017-03-15 | -$38.86M derived: sum of 4 quarters · filed 2017-03-15 |
| 2014-12-31 | -$23.22M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-15 | -$33.54M derived: sum of 2 quarters · filed 2017-03-15 | -$36.53M derived: sum of 3 quarters · filed 2017-03-15 | -$35.81M 10-K · filed 2017-03-15 |
| 2014-09-30 | -$10.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | -$13.31M derived: sum of 2 quarters · filed 2015-11-09 | -$12.60M 10-Q · filed 2015-11-09 | -$17.34M derived: sum of 4 quarters · filed 2016-03-14 |
| 2014-06-30 | -$2.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-10 | -$2.27M 10-Q · filed 2015-08-10 | -$7.02M derived: sum of 3 quarters · filed 2016-03-14 | -$7.20M derived: sum of 4 quarters · filed 2016-03-14 |
| 2014-03-31 | $718.60K 10-Q · filed 2015-05-11 | -$4.03M derived: sum of 2 quarters · filed 2016-03-14 | -$4.21M derived: sum of 3 quarters · filed 2016-03-14 | -$8.53M derived: sum of 4 quarters · filed 2016-03-14 |
| 2013-12-31 | -$4.74M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-14 | -$4.93M derived: sum of 2 quarters · filed 2016-03-14 | -$9.25M derived: sum of 3 quarters · filed 2016-03-14 | -$9.24M 10-K · filed 2016-03-14 |
| 2013-09-30 | -$184.48K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-10 | -$4.50M derived: sum of 2 quarters · filed 2014-11-10 | -$4.49M 10-Q · filed 2014-11-10 | -$2.01M derived: sum of 4 quarters · filed 2015-03-16 |
| 2013-06-30 | -$4.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-11 | -$4.31M 10-Q · filed 2014-08-11 | -$1.83M derived: sum of 3 quarters · filed 2015-03-16 | $1.61M derived: sum of 4 quarters · filed 2015-03-16 |
| 2013-03-31 | $10.80K 10-Q · filed 2014-05-12 | $2.49M derived: sum of 2 quarters · filed 2015-03-16 | $5.93M derived: sum of 3 quarters · filed 2015-03-16 | $6.07M derived: sum of 4 quarters · filed 2015-03-16 |
| 2012-12-31 | $2.48M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-16 | $5.92M derived: sum of 2 quarters · filed 2015-03-16 | $6.06M derived: sum of 3 quarters · filed 2015-03-16 | $5.28M 10-K · filed 2015-03-16 |
| 2012-09-30 | $3.44M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-12 | $3.58M derived: sum of 2 quarters · filed 2013-11-12 | $2.80M 10-Q · filed 2013-11-12 | -$4.31M derived: sum of 4 quarters · filed 2014-03-17 |
| 2012-06-30 | $137.65K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-09 | -$646.61K 10-Q · filed 2013-08-09 | -$7.75M derived: sum of 3 quarters · filed 2014-03-17 | -$7.77M derived: sum of 4 quarters · filed 2014-03-17 |
| 2012-03-31 | -$784.25K 10-Q · filed 2013-05-10 | -$7.89M derived: sum of 2 quarters · filed 2014-03-17 | -$7.91M derived: sum of 3 quarters · filed 2014-03-17 | -$10.05M derived: sum of 4 quarters · filed 2014-03-17 |
| 2011-12-31 | -$7.11M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-17 | -$7.13M derived: sum of 2 quarters · filed 2014-03-17 | -$9.26M derived: sum of 3 quarters · filed 2014-03-17 | -$10.90M 10-K · filed 2014-03-17 |
| 2011-09-30 | -$21.13K derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-07 | -$2.16M derived: sum of 2 quarters · filed 2012-11-07 | -$3.79M 10-Q · filed 2012-11-07 | -$1.52M derived: sum of 4 quarters · filed 2013-03-18 |
| 2011-06-30 | -$2.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-09 | -$3.77M 10-Q · filed 2012-08-09 | -$1.49M derived: sum of 3 quarters · filed 2013-03-18 | $4.12M derived: sum of 4 quarters · filed 2013-03-18 |
| 2011-03-31 | -$1.64M 10-Q · filed 2012-05-09 | $641.47K derived: sum of 2 quarters · filed 2013-03-18 | $6.26M derived: sum of 3 quarters · filed 2013-03-18 | |
| 2010-12-31 | $2.28M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-18 | $7.89M derived: sum of 2 quarters · filed 2013-03-18 | $11.44M 10-K · filed 2013-03-18 | |
| 2010-09-30 | $5.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-07 | $9.16M 10-Q · filed 2011-11-07 | ||
| 2010-06-30 | $3.54M 10-Q · filed 2011-08-05 | |||
| 2009-12-31 | $1.45M 10-K · filed 2012-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |